Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Citation: Buononato D, Licata G, Gambardella A, De Rosa A, Calabrese G, Argenziano G. Tildrakizumab: successfull response in two patients with psoriatic arthritis. Dermatol Pract Concept. 2022;12(2):e2022049. DOI: https://doi.org/10.5826/dpc.1202a49

Accepted: July 22, 2021; Published: April 2022

Copyright: ©2022 Buononato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: None.

Authorship: Both authors have contributed significantly to this publication

Corresponding author: Dario Buononato, MD, Department of Dermatology University of Campania “Luigi Vanvitelli” via Sergio Pansini, 5, 80131 Napoli, Italy. Email: dario.buononato@gmail.com

Abstract

Keywords : tildrakizumab, psoriatic arthritis, psoriasis, psoriasis treatment

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

1. Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019 Sep; 206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6. PMID: 30196070; PMCID: PMC6401348. 2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.